PASD1 is a potential multiple myeloma–associated antigen

Sahota, Surinder S.; Goonewardena, C. Madusha; Cooper, C.D.O.; Liggins, Amanda P.; Ait-Tahar, Kamal; Zojer, Niklas; Stevenson, Freda K.; Banham, Alison H.; Pulford, Karen

doi:10.1182/blood-2006-04-014621

Cited by 21 publications

(33 citation statements)

References 6 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13,16,34,[39][40] A recently published signature for highrisk disease contains the genes GAGE1 and GAGE12 which further confirms the relationship between CTA genes and prognosis. 41 Cancer testis antigen expression in MM haematologica | 2011; 96 (11)Cluster analysis further confirms the correlation between different CTAs and especially those located on chromosome X. In cluster 15, part of the prognostically important set of clusters in the newly diagnosed MM cases and the most important cluster in relapse cases, the top 10 overrepresented genes are all derived from chromosome X.…”

Section: Discussionmentioning

confidence: 56%

“…Eighty-seven CTA genes had a presence call frequency of more than 5% and were discussed in the main body of this report. It should be noted that a presence call for any given Cancer testis antigen expression in MM haematologica | 2011; 96 (11)gene using the mas5 algorithm represents a robust level of quantifiable mRNA.…”

Section: Preprocessing and Gene Selectionmentioning

confidence: 99%

“…CTA expression after treatment has been shown for a limited number of CTAs, including PASD1, CTAG1B and MAGEC1/CT7. [11][12][13][14][15] In addition, in MM, expression of CTA genes has been shown to be strongly correlated to clinical outcome, i.e. presence of CTA expression has been linked to shorter survival.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy

Duin¹,

Broyl²,

Knegt³

et al. 2011

Haematologica

View full text Add to dashboard Cite

The online version of this article has a Supplementary Appendix. BackgroundIn multiple myeloma, expression of cancer testis antigens may provide prognostic markers and potential targets for immunotherapy. Expression at relapse has not yet been evaluated for a large panel of cancer testis antigens which can be classified by varying expression in normal tissue: restricted to testis, expressed in testis and brain and not restricted but selectively expressed in testis. Design and MethodsEvaluation of cancer testis antigen expression was made in newly diagnosed multiple myeloma cases (HOVON-65/GMMG-HD4 trial; n=320) and in relapse cases (APEX, SUMMIT, CREST trials; n=264). Presence of expression using Affymetrix GeneChips was determined for 123 cancer testis antigens. Of these 87 had a frequency of more than 5% in the newly diagnosed and relapsed patients, and were evaluated in detail. ResultsTissue restriction was known for 58 out of 87 cancer testis antigens. A significantly lower frequency of presence calls in the relapsed compared to newly diagnosed cases was found for 3 out of 13 testis restricted genes, 2 out of 7 testis/brain restricted genes, and 17 out of 38 testis selective genes. MAGEC1, MAGEB2 and SSX1 were the most frequent testis-restricted cancer testis antigens in both data sets. Multivariate analysis demonstrated that presence of MAGEA6 and CDCA1 were clearly associated with shorter progression free survival, and presence of MAGEA9 with shorter overall survival in the set of newly diagnosed cases. In the set of relapse cases, presence of CTAG2 was associated with shorter progression free survival and presence of SSX1 with shorter overall survival. ConclusionsRelapsed multiple myeloma reveals extensive cancer testis antigen expression. Cancer testis antigens are confirmed as useful prognostic markers in newly diagnosed multiple myeloma patients and in relapsed multiple myeloma patients.The HOVON-65/GMMG-HD4 trial is registered under Dutch trial register n. respectively.

show abstract

Section: Discussionmentioning

confidence: 56%

Section: Preprocessing and Gene Selectionmentioning

confidence: 99%

See 1 more Smart Citation

Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy

Duin¹,

Broyl²,

Knegt³

et al. 2011

Haematologica

View full text Add to dashboard Cite

show abstract

“…Nuclear labeling was seen with both antibodies in Granta519 (mantle cell lymphoma), KM-H2 (Hodgkin's lymphoma) (Figure 1g and h), K562 (chronic myeloid leukemia) cells and Thiel (multiple myeloma). 7 Western blotting studies supported the heterogeneity of PASD1 expression in cell lines (Figure 1i). Both antibodies Letters to the Editor labeled 100 kDa proteins in lysates of PASD1_v2 COS cell transfectants, Thiel and KM-H2 cell lines suggesting that the nuclear labeling observed was that of the PASD1_v2 isoform (predicted molecular weight 87.5 kDa).…”

mentioning

confidence: 75%

PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy

et al. 2006

View full text Add to dashboard Cite

“…Transcripts found in 33% (4 of 12) acute myeloid leukaemia patients, 1 of 6 chronic myeloid leukaemia patients and 4 of 16 cell lines (Guinn et al, 2005). Transcripts have been found in 5 of 11 multiple myeloma cell lines including THIEL and RPMI8226, and 14 of 16 primary multiple myeloma samples (Sahota et al, 2006), 22 of 25 B-and T-cell malignancy cell lines (Liggins et al, 2010). …”

Section: Transcriptionmentioning

confidence: 99%